MARKET

ABMD

ABMD

Abiomed Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

249.19
-0.03
-0.01%
After Hours: 249.19 0 0.00% 17:00 05/24 EDT
OPEN
244.69
PREV CLOSE
249.22
HIGH
249.43
LOW
242.89
VOLUME
403.50K
TURNOVER
0
52 WEEK HIGH
379.30
52 WEEK LOW
226.46
MARKET CAP
11.35B
P/E (TTM)
84.05
1D
5D
1M
3M
1Y
5Y
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements To Improve Cardiogenic Shock Outcomes
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes Abiomed (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature
Benzinga · 6d ago
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Zacks · 05/16 14:48
Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks · 05/12 13:45
Should Weakness in Abiomed, Inc.'s (NASDAQ:ABMD) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Abiomed's (NASDAQ:ABMD) recent performance, when its stock has declined 19...
Simply Wall St. · 05/08 14:40
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Abiomed, Inc.
MT Newswires · 05/02 16:49
Integra (IART) Q1 Earnings Top Estimates, Margins Expand
Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.
Zacks · 05/02 12:37
QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up
QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.
Zacks · 04/29 14:30
Recap: Abiomed Q4 Earnings
  Abiomed (NASDAQ:ABMD) reported its Q4 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 04/28 13:54
More
No Data
Learn about the latest financial forecast of ABMD. Analyze the recent business situations of Abiomed Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
20.00%Buy
50.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average ABMD stock price target is 347.50 with a high estimate of 425.00 and a low estimate of 260.00.
High425.00
Average347.50
Low260.00
Current 249.19
EPS
Actual
Estimate
0.290.580.871.16
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Institutional Holdings
Institutions: 732
Institutional Holdings: 49.08M
% Owned: 107.84%
Shares Outstanding: 45.56M
TypeInstitutionsShares
Increased
159
2.06M
New
61
576.51K
Decreased
176
1.48M
Sold Out
56
444.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.22%
Healthcare Equipment & Supplies
-0.35%
Key Executives
Chairman/Director/President/Chief Executive Officer
Michael Minogue
Chief Financial Officer/Vice President
Todd Trapp
Vice President/General Counsel/Secretary
Marc Began
Vice President
Andrew Greenfield
Lead Director/Independent Director
Dorothy Puhy
Independent Director
Paula Johnson
Independent Director
Jeannine Rivet
Independent Director
Myron Rolle
Independent Director
Eric Rose
Independent Director
Martin Sutter
Independent Director
Paul Thomas
Independent Director
Christopher Van Gorder
No Data
No Data
About ABMD
ABIOMED, Inc. is a provider of medical devices, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to improve blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. Its operating segment includes the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. Its existing products include Impella 2.5, Impella CP, Impella 5.0 and Impella LD. The Impella 2.5 device is a percutaneous micro heart pump with an integrated motor and sensors. The Impella CP device provides blood flow of approximately one liter more per minute than the Impella 2.5 device.

Webull offers kinds of ABIOMED, Inc. stock information, including NASDAQ:ABMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABMD stock methods without spending real money on the virtual paper trading platform.